[{"address1": "11 Commerce Drive", "address2": "First Floor", "city": "Cranford", "state": "NJ", "zip": "07016", "country": "United States", "phone": "908 967 6677", "website": "https://citiuspharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. The company was founded in 2007 and is headquartered in Cranford, New Jersey.", "fullTimeEmployees": 22, "companyOfficers": [{"maxAge": 1, "name": "Mr. Leonard L. Mazur", "age": 78, "title": "Co-Founder, CEO, Chairman & Secretary", "yearBorn": 1945, "fiscalYear": 2023, "totalPay": 676875, "exercisedValue": 0, "unexercisedValue": 2520}, {"maxAge": 1, "name": "Mr. Myron Z. Holubiak", "age": 76, "title": "Co-Founder & Executive Vice Chairman", "yearBorn": 1947, "fiscalYear": 2023, "totalPay": 641250, "exercisedValue": 0, "unexercisedValue": 2520}, {"maxAge": 1, "name": "Dr. Myron S. Czuczman M.D.", "age": 63, "title": "Executive VP & Chief Medical Officer", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 571375, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jaime  Bartushak", "age": 55, "title": "Chief Business Officer, CFO & Chief Accounting Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 527967, "exercisedValue": 0, "unexercisedValue": 44333}, {"maxAge": 1, "name": "Mr. Gary F. Talarico", "age": 68, "title": "Executive Vice President of Operations", "yearBorn": 1955, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ilanit  Allen", "title": "Vice President of Investor Relations & Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Alan  Lader Ph.D.", "title": "Senior VP and Head of Clinical Operations & Quality Assurance", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Dhananjay G. Wadekar", "age": 69, "title": "Senior Vice President of Business Strategy", "yearBorn": 1954, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kelly  Creighton Ph.D.", "title": "Executive Vice President of Chemistry, Manufacturing & Controls", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nikolas  Burlew", "title": "Executive Vice President of Quality Assurance", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.3284, "open": 0.3185, "dayLow": 0.1875, "dayHigh": 0.3279, "regularMarketPreviousClose": 0.3284, "regularMarketOpen": 0.3185, "regularMarketDayLow": 0.1875, "regularMarketDayHigh": 0.3279, "beta": 1.663, "forwardPE": 1.3957143, "volume": 5301431, "regularMarketVolume": 5301431, "averageVolume": 1142464, "averageVolume10days": 2274740, "averageDailyVolume10Day": 2274740, "bid": 0.1674, "ask": 0.249, "bidSize": 200, "askSize": 200, "marketCap": 35313664, "fiftyTwoWeekLow": 0.1875, "fiftyTwoWeekHigh": 1.07, "fiftyDayAverage": 0.43696, "twoHundredDayAverage": 0.652765, "currency": "USD", "enterpriseValue": 42359424, "floatShares": 158246781, "sharesOutstanding": 180724992, "sharesShort": 11787635, "sharesShortPriorMonth": 12768363, "sharesShortPreviousMonthDate": 1727654400, "dateShortInterest": 1730332800, "sharesPercentSharesOut": 0.0652, "heldPercentInsiders": 0.0681, "heldPercentInstitutions": 0.13442001, "shortRatio": 13.22, "shortPercentOfFloat": 0.07, "impliedSharesOutstanding": 180724992, "bookValue": 0.474, "priceToBook": 0.41223627, "lastFiscalYearEnd": 1696032000, "nextFiscalYearEnd": 1727654400, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -39765352, "trailingEps": -0.24, "forwardEps": 0.19, "lastSplitFactor": "1:15", "lastSplitDate": 1496966400, "enterpriseToEbitda": -1.031, "52WeekChange": -0.5756792, "SandP52WeekChange": 0.31793165, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "CTXR", "underlyingSymbol": "CTXR", "shortName": "Citius Pharmaceuticals, Inc.", "longName": "Citius Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1412256600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "c2faef45-30de-37ba-b921-6b91e4daf573", "messageBoardId": "finmb_272471835", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.1954, "targetHighPrice": 6.0, "targetLowPrice": 4.0, "targetMeanPrice": 4.66667, "targetMedianPrice": 4.0, "recommendationMean": 1.66667, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 17911192, "totalCashPerShare": 0.099, "ebitda": -41067916, "totalDebt": 320011, "quickRatio": 4.314, "currentRatio": 6.745, "debtToEquity": 0.371, "returnOnAssets": -0.24741, "returnOnEquity": -0.41491002, "freeCashflow": -16828150, "operatingCashflow": -29088902, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-11-15"}]